Pacifica Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Pacifica Partners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,500	Closed	-$1.29K	–	511
2023 Q1	$1.29K	Hold	3,500	–	–	﹤0.01%	457
2022 Q4	$2.6K	Hold	3,500	–	–	﹤0.01%	412
2022 Q3	$7K	Hold	3,500	–	–	0.01%	340
2022 Q2	$7K	Buy	+3,500	New	+$6.05K	﹤0.01%	345

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Pacifica Partners's SRNE Position: Q2 2023 in Review

Pacifica Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 3,500 shares — an estimated $1.29K sold.

Pacifica Partners first reported a position in SRNE in Q2 2022 and held it in 4 quarters. The position peaked at $7K in Q3 2022. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Pacifica Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Pacifica Partners sold 3,500 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $1.29K.
Pacifica Partners first reported a position in Sorrento Therapeutics, Inc. in Q2 2022 and held it in 4 quarters.
Pacifica Partners's Sorrento Therapeutics, Inc. position peaked at $7K in Q3 2022.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Pacifica Partners's 13F filing for Q2 2023, filed 17 Jul 2023.